$6.08
3.58% yesterday
Nasdaq, Dec 24, 07:01 pm CET
ISIN
US1374041093
Symbol
CADL

Candel Therapeutics Inc Stock price

$6.08
+1.55 34.22% 1M
+1.23 25.36% 6M
-2.60 29.95% YTD
-2.72 30.91% 1Y
+4.56 300.00% 3Y
-0.92 13.14% 5Y
-0.92 13.14% 10Y
-0.92 13.14% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.21 3.58%
ISIN
US1374041093
Symbol
CADL
Industry

Key metrics

Basic
Market capitalization
$333.8m
Enterprise Value
$252.0m
Net debt
positive
Cash
$87.0m
Shares outstanding
54.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.2
Financial Health
Equity Ratio
62.1%
Return on Equity
-83.2%
ROCE
-49.2%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-39.3m | $-46.7m
EBIT
$-40.7m | $-47.6m
Net Income
$-22.8m | $-23.3m
Free Cash Flow
$-33.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-13.7% | -44.3%
EBIT
-14.4% | -42.8%
Net Income
56.4% | 57.7%
Free Cash Flow
-17.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.4
FCF per Share
$-0.6
Short interest
19.0%
Employees
38
Rev per Employee
$0.0
Show more

Is Candel Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Candel Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Candel Therapeutics Inc forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Candel Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Candel Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
19% 19%
-
- Research and Development Expense 23 23
12% 12%
-
-39 -39
14% 14%
-
- Depreciation and Amortization 1.38 1.38
37% 37%
-
EBIT (Operating Income) EBIT -41 -41
14% 14%
-
Net Profit -23 -23
56% 56%
-

In millions USD.

Don't miss a Thing! We will send you all news about Candel Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Candel Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about one month ago
NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced it will host a virtual Research and Development (R&D) Event from 11:00 am – 1:45 pm ET on Friday, December 5, 2025.
Positive
Proactive Investors
about one month ago
Candel Therapeutics Inc (NASDAQ:CADL) reported encouraging clinical progress across its cancer immunotherapy pipeline, along with the release of its third quarter 2025 financial results. The company recently presented new Phase 3 subgroup analyses of CAN-2409 in localized prostate cancer showing statistically significant improvement in disease-free survival and updated survival data from its Ph...
Neutral
GlobeNewsWire
about one month ago
Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific disease-free survival (DFS), independent of radiation therapy modality utilized                                                         Company plans to initiate pivotal phase 3 c...
More Candel Therapeutics Inc News

Company Profile

Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Head office United States
CEO Paul-Peter Tak
Employees 38
Founded 2002
Website www.candeltx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today